Crossject Société Anonyme (EPA:ALCJ)

France · Delayed Price · Currency is EUR

1.686

-0.038 (-2.20%)

Jul 13, 2026, 5:35 PM CET

-1.98% (1Y)

Market Cap	91.79M +15.4%
Revenue (ttm)	2.57M -37.6%
Net Income	-10.37M
EPS	-0.20
Shares Out	54.44M
PE Ratio	n/a
Forward PE	4.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	79,990
Open	1.740
Previous Close	1.724
Day's Range	1.684 - 1.740
52-Week Range	1.346 - 2.695
Beta	0.52
Analysts	Strong Buy
Price Target	4.40 (+160.97%)
Earnings Date	Sep 23, 2026

About Crossject Société Anonyme

Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is dev... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 2001

Employees 99

Stock Exchange Euronext Paris

Ticker Symbol ALCJ

Full Company Profile

Financial Performance

In 2025, Crossject Société Anonyme's revenue was 2.57 million, a decrease of -37.59% compared to the previous year's 4.12 million. Losses were -10.37 million, -18.97% less than in 2024.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for ALCJ stock is "Strong Buy." The 12-month stock price target is €4.40, which is an increase of 160.97% from the latest price.

Price Target

€4.40

(160.97% upside)

Analyst Consensus: Strong Buy

Stock Forecasts